Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants

Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants

Abstract Background FKB327 has been developed as a biosimilar of the adalimumab reference product (RP). We compared the pharmacokinetics (PK), safety, and immunogenicity of FKB327 with those of the adalimumab RP after a single dose by subcutaneous (SC) injection in Japanese male participants. Method...

Full description

Bibliographic Details
Main Authors: Takuma Yonemura, Rie Yazawa, Miwa Haranaka, Kazuki Kawakami, Masayuki Takanuma, Takumi Kanzo, Dimitris Stefanidis, Yasumasa Arai
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Pharmacology and Toxicology
Subjects:
Adalimumab
Bioequivalence
Biosimilar
FKB327
Japanese
Pharmacokinetics
Online Access:https://doi.org/10.1186/s40360-021-00545-3

Internet

https://doi.org/10.1186/s40360-021-00545-3

Similar Items